The metabolism of deuterated analogues of chlorambucil by the rat

https://doi.org/10.1016/0009-2797(79)90162-5Get rights and content

Abstract

The antitumour agent chlorambucil {4[4-bis(2-chloroethyl)aminophenyl]butyric acid} is converted by β-oxidation in vivo into phenylacetic mustard {2[4-bis(2-chloroethyl)aminophenyl]acetic acid}. This process may be disadvantageous from a therapeutic viewpoint since the metabolite has half the therapeutic index of the parent drug against the Walker 256 carcinoma in rats. In seeking to retard β-oxidation, selectively deuterated analogues have been synthesised and administered to rats. Plasma levels of phenylacetic mustard after giving chlorambucil-β-d2 were lower than those given by unlabelled drug, but the therapeutic activity was not significantly altered by deuteration.

A dehydro derivative of chlorambucil was detected as an intermediate in the β-oxidation pathway. The isotopic compositions of this metabolite, and of recovered chlorambucil, were measured in plasma samples taken after giving labelled chlorambucil (α-d2 and β-d2 variants) to rats. Deuterium was almost totally lost from the α-d2 form and from its metabolite after 30 min and partially lost in 10 min. The β-d2 variant and its dehydro-derivative retained the label. Possible mechanisms for deuteration loss are discussed.

The design of novel analogues, based on these metabolic studies, is proposed.

References (19)

There are more references available in the full text version of this article.

Cited by (0)

Present address: Medical Research Council Toxicology Unit, Woodmansterne Road, Carshalton, Surrey.

Visiting Scientist, Institute of Cancer Research, 1977.

View full text